(Q30978373)

27 June 2017

1 reference

title

A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine (English)

1 reference

27 June 2017

1 reference

G Dailey

1

1 reference

27 June 2017

F Lavernia

series ordinal

2

1 reference

27 June 2017

publication date

3 July 2015

1 reference

Diabetes, Obesity and Metabolism

27 June 2017

published in

1 reference

27 June 2017

volume

17

1 reference

27 June 2017

issue

12

1 reference

27 June 2017

page(s)

1107-1114

1 reference

Measurement of insulin absorption and insulin action

27 June 2017

cites work

1 reference

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

21 January 2018

1 reference

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

21 January 2018

1 reference

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

21 January 2018

1 reference

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

21 January 2018

1 reference

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten

21 January 2018

1 reference

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

21 January 2018

1 reference

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

21 January 2018

1 reference

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

21 January 2018

1 reference

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

21 January 2018

1 reference

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

21 January 2018

1 reference

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

21 January 2018

1 reference

Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials

21 January 2018

1 reference

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec

21 January 2018

1 reference

Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare).

21 January 2018

1 reference

Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study

21 January 2018

1 reference

Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.

21 January 2018

1 reference

Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12531

1 reference

27 June 2017

1 reference